Greg is currently Senior Vice President and Lifecycle Leader, Advanced Staining Assays at Ventana Medical Systems, a member of the Roche Group. In this role, Greg is responsible for Ventana’s entire market leading portfolio of cancer assays, ranging from standard-of-care diagnostics for all major cancers to novel multiplex tests and companion diagnostics. These assays are used to inform treatment of more than half of all cancer patients in the US and almost half of all cancer patients worldwide.
Greg’s career has been focused at the intersection of business, medicine, and novel technologies. His experience spans personalized medicine, translational research, and genomics as well as high growth companies both large and small. Previously, he was Chief Operating Officer of CELLective DX / Cellpoint Diagnostics, a startup cancer molecular diagnostics company developing a novel platform for analyzing circulating tumor cells to predict and monitor treatment efficacy. Greg has also held multiple senior operating and general management roles at Affymetrix, the pioneer of DNA microarrays. His responsibilities there included VP Molecular Diagnostics, where he was responsible for products, partnerships, and business, and VP DNA Products, where he started and built the genetics business from zero to $100 million in revenue. Greg has consulted to and advised numerous health care startups, and previously worked in venture capital with Bay City Capital and in management consulting with McKinsey & Company.
Greg received his MBA from Stanford University and his AB in molecular biology, summa cum laude, from Princeton University. His spare time is mostly spent with his family, chasing his two small children.